Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...